Siemens Healthineers AG: insider trades · Germany · BaFin

About Siemens Healthineers AG

Siemens Healthineers AG is a global medical technology group listed on Xetra/Frankfurt (DAX/MDAX/SDAX) in Germany under the ticker SHL.DE. The company supplies healthcare technologies to hospitals, laboratories and care providers, making it a capital-intensive medtech franchise with exposure to healthcare investment cycles. Its headquarters are in Erlangen, Bavaria, within Siemens’ historic industrial ecosystem. Siemens Healthineers emphasizes more than 125 years of heritage in healthcare technology, while its current corporate structure was established with the spin-off and IPO completed in 2018. ([siemens-healthineers.com](https://www.siemens-healthineers.com/press/features/pf-hq-opening?utm_source=openai)) The business is organized around three major strategic pillars. Imaging covers diagnostic and interventional imaging, including MRI, CT, ultrasound, X-ray and angiography platforms. Diagnostics includes laboratory diagnostics, molecular medicine, point-of-care testing and related services. The group has also expanded its treatment exposure through Varian and Advanced Therapies, which are now central to its therapy strategy. This structure allows Siemens Healthineers to address the full care continuum, from detection to treatment, while increasingly embedding artificial intelligence and digital workflows across the portfolio. ([siemens-healthineers.com](https://www.siemens-healthineers.com/press/releases/cmd2025?utm_source=openai)) In competitive terms, Siemens Healthineers is one of the leading players in medical imaging globally and holds strong positions in several premium categories, particularly interventional imaging, CT and integrated cancer care. Its competitive advantage rests on a large installed base, long-term customer relationships with healthcare systems, recurring service revenue and a sustained innovation pipeline. The company also highlights strengths in digital, data and AI, as well as digital patient twins and precision therapy. Geographically, it has a broad global footprint spanning Europe, North America and Asia-Pacific, with a particularly significant presence in the United States. ([siemens-healthineers.com](https://www.siemens-healthineers.com/de/about?utm_source=openai)) Recent developments point to solid operational execution. For fiscal 2025, ended September 30, 2025, Siemens Healthineers reported comparable revenue growth of 5.9%, adjusted EBIT of nearly €3.9 billion, an adjusted EBIT margin of 16.5%, and free cash flow of around €2.7 billion. In November 2025, the group also unveiled its new strategic phase, “Elevating Health Globally,” reorganizing financial reporting around Imaging, Precision Therapy and Diagnostics, while placing greater emphasis on AI and clinical partnerships. In early 2026, Siemens Healthineers continued to announce product launches and portfolio extensions in interventional imaging and oncology-related applications, underscoring an active innovation pipeline. ([siemens-healthineers.com](https://www.siemens-healthineers.com/press/releases/2025q4?utm_source=openai))